MX2023013392A - Anticuerpos para tratar alfa-sinucleinopatias. - Google Patents

Anticuerpos para tratar alfa-sinucleinopatias.

Info

Publication number
MX2023013392A
MX2023013392A MX2023013392A MX2023013392A MX2023013392A MX 2023013392 A MX2023013392 A MX 2023013392A MX 2023013392 A MX2023013392 A MX 2023013392A MX 2023013392 A MX2023013392 A MX 2023013392A MX 2023013392 A MX2023013392 A MX 2023013392A
Authority
MX
Mexico
Prior art keywords
alpha
synucleinopathies
antibodies
binding proteins
synuclein
Prior art date
Application number
MX2023013392A
Other languages
English (en)
Inventor
Donghwan Kim
Jinhyung Ahn
Sungwon An
Dongin Kim
Juhee Kim
Jinwon Jung
Byungje Sung
Bora Lee
Youngdon Pak
Daehae Song
Yong - Gyu SON
Kyungjin Park
Hyesu Yun
Jung - Won SHIN
Original Assignee
Abl Bio Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abl Bio Incorporated filed Critical Abl Bio Incorporated
Publication of MX2023013392A publication Critical patent/MX2023013392A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente descripción proporciona proteínas de unión aisladas, tales como anticuerpos humanizados y fragmentos de unión a antígenos de los mismos que se dirigen a la alfa-sinucleína, incluyendo proteínas de unión aisladas multiespecíficas que se dirigen tanto a la alfa-sinucleína como al receptor del factor de crecimiento similar a la insulina 1. También se proporcionan métodos de uso de las proteínas de unión para tratar las alfa-sinucleinopatías.
MX2023013392A 2021-05-12 2022-05-12 Anticuerpos para tratar alfa-sinucleinopatias. MX2023013392A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20210061407 2021-05-12
PCT/IB2022/054445 WO2022238961A1 (en) 2021-05-12 2022-05-12 Antibodies for treating alpha-synucleinopathies

Publications (1)

Publication Number Publication Date
MX2023013392A true MX2023013392A (es) 2024-02-15

Family

ID=84028418

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013392A MX2023013392A (es) 2021-05-12 2022-05-12 Anticuerpos para tratar alfa-sinucleinopatias.

Country Status (14)

Country Link
US (1) US20220380446A1 (es)
EP (1) EP4340881A1 (es)
JP (1) JP2024520905A (es)
KR (1) KR20240031229A (es)
CN (1) CN117858721A (es)
AR (1) AR125857A1 (es)
AU (1) AU2022271678A1 (es)
BR (1) BR112023023284A2 (es)
CA (1) CA3219659A1 (es)
CO (1) CO2023015859A2 (es)
IL (1) IL308393A (es)
MX (1) MX2023013392A (es)
TW (1) TW202309076A (es)
WO (1) WO2022238961A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019008029A (es) 2017-01-06 2019-12-11 Abl Bio Inc Anticuerpo anti-alfa-sinucleina y su uso.
US12071483B1 (en) 2017-12-14 2024-08-27 Abl Bio Inc. Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018128454A1 (ko) * 2017-01-06 2018-07-12 에이비엘바이오 주식회사 항 α-SYN 항체 및 그 용도
CA3082559A1 (en) * 2017-11-17 2019-05-23 Abl Bio Inc. Antibodies to .alpha.-synuclein and uses thereof
EP3985022A4 (en) * 2019-06-14 2023-08-02 ABL Bio, Inc. BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ITS USE

Also Published As

Publication number Publication date
IL308393A (en) 2024-01-01
JP2024520905A (ja) 2024-05-27
KR20240031229A (ko) 2024-03-07
TW202309076A (zh) 2023-03-01
AR125857A1 (es) 2023-08-16
WO2022238961A1 (en) 2022-11-17
US20220380446A1 (en) 2022-12-01
BR112023023284A2 (pt) 2024-01-30
CO2023015859A2 (es) 2024-02-26
CN117858721A (zh) 2024-04-09
AU2022271678A1 (en) 2024-01-04
CA3219659A1 (en) 2022-11-17
EP4340881A1 (en) 2024-03-27

Similar Documents

Publication Publication Date Title
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
MY198034A (en) Tumor-targeted agonistic cd28 antigen binding molecules
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
MX2023013392A (es) Anticuerpos para tratar alfa-sinucleinopatias.
NZ777032A (en) Anti-nkg2a antibodies and uses thereof
MX2022009306A (es) Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
EA201891428A1 (ru) Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
EA202091747A1 (ru) Составы антитела b7-h4
MX2021005323A (es) Metodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn.
MX2022002682A (es) Anticuerpos anti-cd73.
AU2019433019A8 (en) Antibodies binding CD40 and uses thereof
MX2021014193A (es) Moleculas de enlace biespecificas anti-ror1/anti-cd3.
MX2020011588A (es) Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.
MX2020011914A (es) Anticuerpos anti-dll3 y usos de los mismos.
MX2022005866A (es) Anticuerpos biparatopicos frente a cd73.
CR20220078A (es) Anticuerpos anti-ms4a4a y métodos de uso de los mismos
MX2021004454A (es) Anticuerpos anti-sinucleina.
CR20220505A (es) Anticuerpos anti-phf-tau y usos de estos
PH12020551187A1 (en) Bispecific antigen-binding molecules and methods of use
MX2023001776A (es) Anticuerpos contra ilt2 y uso de los mismos.
MX2022005862A (es) Metodos de tratamiento de anemia hemolitica autoinmune caliente mediante el uso de anticuerpos anti-fcrn.
EA202092122A1 (ru) Антитела против tip-1 и их применения
AU2018345715A8 (en) DNA monoclonal antibodies targeting CTLA-4 for the treatment and prevention of cancer